Replimune Group Inc (REPL)

(75% Positive) REPLIMUNE GROUP, INC. (REPL) Announces Enrollment Update for results Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Instil Bio Inc (TIL)

(10% Negative) Instil Bio, Inc. (TIL) Announces Delay in patients Trials for cancer Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Efficacy Assessment